Tumor Biology

, Volume 35, Issue 6, pp 5159–5165 | Cite as

EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma

  • Naohisa Futamura
  • Yoshihiro Nishida
  • Hiroshi Urakawa
  • Eiji Kozawa
  • Kunihiro Ikuta
  • Shunsuke Hamada
  • Naoki Ishiguro
Research Article


Several studies have focused on the relationships between the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and the prognosis of patients with malignant tumors. However, few of these have investigated the expression of EMMPRIN in osteosarcoma. We examined expression levels of EMMPRIN immunohistochemically in 53 cases of high-grade osteosarcoma of the extremities and analyzed the correlation of its expression with patient prognosis. The correlation between matrix metalloproteinases (MMPs) and EMMPRIN expression and the prognostic value of co-expression were also analyzed. Staining positivity for EMMPRIN was negative in 7 cases, low in 17, moderate in 19, and strong in 10. The overall and disease-free survivals (OS and DFS) in patients with higher EMMPRIN expression (strong-moderate) were significantly lower than those in the lower (weak-negative) group (0.037 and 0.024, respectively). In multivariate analysis, age (P = 0.004), location (P = 0.046), and EMMPRIN expression (P = 0.038) were significant prognostic factors for overall survival. EMMPRIN expression (P = 0.024) was also a significant prognostic factor for disease-free survival. Co-expression analyses of EMMPRIN and MMPs revealed that strong co-expression of EMMPRIN and membrane-type 1 (MT1)-MMP had a poor prognostic value (P = 0.056 for DFS, P = 0.006 for OS). EMMPRIN expression and co-expression with MMPs well predict the prognosis of patients with extremity osteosarcoma, making EMMPRIN a possible therapeutic target in these patients.


EMMPRIN Osteosarcoma Matrix metalloproteinase Prognosis 



We thank Miss Eri Ishihara for her secretarial assistance. We are also grateful to Drs. Mitsutoshi Uchibori, Eisuke Arai, Satoshi Tsukushi, and Hiroatsu Nakashima for the collection of samples and data. This work was supported in part by the Ministry of Education, Culture, Sports, Science and Technology of Japan [Grant-in-Aid 20591751 for Scientific Research (C)] and by the Suzuken Memorial Foundation.

Conflicts of interest



  1. 1.
    Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2005;106:1154–61.CrossRefGoogle Scholar
  2. 2.
    Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer. 1992;69:698–708.CrossRefPubMedGoogle Scholar
  4. 4.
    Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol. 2007;96:118–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004;429:286–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452–8.PubMedGoogle Scholar
  7. 7.
    Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994;12:2699–705.PubMedGoogle Scholar
  8. 8.
    Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol. 2006;28:33–42.PubMedGoogle Scholar
  9. 9.
    Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res. 2009;467:2932–8.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434–9.PubMedGoogle Scholar
  11. 11.
    Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 2006;56:359–67.CrossRefPubMedGoogle Scholar
  12. 12.
    Donadio AC, Remedi MM, Susperreguy S, Frede S, Gilardoni MB, Tang Y, et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinases (MMPs) as regulators of tumor–host interaction in a spontaneous metastasis model in rats. Histochem Cell Biol. 2008;130:1155–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9:267–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Marieb EA, Zoltan-Jones A, Li R, Misra S, Ghatak S, Cao J, et al. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res. 2004;64:1229–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Newman JR, Bohannon IA, Zhang W, Skipper JB, Grizzle WE, Rosenthal EL. Modulation of tumor cell growth in vivo by extracellular matrix metalloprotease inducer. Arch Otolaryngol Head Neck Surg. 2008;134:1218–24.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Boye K, Nesland JM, Sandstad B, Haugen MH, Maelandsmo GM, Flatmark K. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. Br J Cancer. 2012;107:667–74.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Chen T, Zhu J. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol. 2010;27:1185–91.CrossRefPubMedGoogle Scholar
  18. 18.
    Qin Z, Dai L, Bratoeva M, Slomiany MG, Toole BP, Parsons C. Cooperative roles for emmprin and LYVE-1 in the regulation of chemoresistance for primary effusion lymphoma. Leukemia. 2011;25:1598–609.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Yang X, Dai J, Li T, Zhang P, Ma Q, Li Y, et al. Expression of EMMPRIN in adenoid cystic carcinoma of salivary glands: correlation with tumor progression and patients’ prognosis. Oral Oncol. 2010;46:755–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Lu Q, Lv G, Kim A, Ha JM, Kim S. Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma. Oncol Lett. 2013;5:201–7.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 2011;20:13–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Sameshima T, Nabeshima K, Toole BP, Yokogami K, Okada Y, Goya T, et al. Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer. 2000;88:21–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Buergy D, Fuchs T, Kambakamba P, Mudduluru G, Maurer G, Post S, et al. Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer. Cancer. 2009;115:4667–78.CrossRefPubMedGoogle Scholar
  24. 24.
    Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer. 2002;99:520–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol. 2003;54:371–89.CrossRefPubMedGoogle Scholar
  26. 26.
    Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis. 2002;19:697–702.CrossRefPubMedGoogle Scholar
  27. 27.
    Sameshima T, Nabeshima K, Toole BP, Yokogami K, Okada Y, Goya T, et al. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett. 2000;157:177–84.CrossRefPubMedGoogle Scholar
  28. 28.
    Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001;61:2276–81.PubMedGoogle Scholar
  29. 29.
    Nishibaba R, Higashi Y, Su J, Furukawa T, Kawai K, Kanemura T. CD147-targeting siRNA inhibits cell-matrix adhesion of human malignant melanoma cells by phosphorylating focal adhesion kinase. J Dermatr. 2012;39:63–7.CrossRefGoogle Scholar
  30. 30.
    Yang X, Zhang P, Ma Q, Kong L, Li Y, Liu B, et al. EMMPRIN silencing inhibits proliferation and perineural invasion of human salivary adenoid cystic carcinoma cells in vitro and in vivo. Cancer Biol Ther. 2012;13:85–91.CrossRefPubMedGoogle Scholar
  31. 31.
    Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat. 2008;11:110–21.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Zhu C, Pan Y, He B, Wang B, Xu Y, Qu L, et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells. Oncol Rep. 2011;25:425–32.CrossRefPubMedGoogle Scholar
  33. 33.
    Lee JA, Kim MS, Kim DH, Lim JS, Park KD, Song WS, et al. Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. Pediatr Blood Cancer. 2009;52:340–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for non-metastatic osteogenic sarcoma. The Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5–15.PubMedGoogle Scholar
  35. 35.
    Szendroi M, Pápai Z, Koós R, Illés T. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. J Surg Oncol. 2000;73:87–94.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Naohisa Futamura
    • 1
  • Yoshihiro Nishida
    • 1
  • Hiroshi Urakawa
    • 2
  • Eiji Kozawa
    • 1
  • Kunihiro Ikuta
    • 1
  • Shunsuke Hamada
    • 1
  • Naoki Ishiguro
    • 1
  1. 1.Department of Orthopaedic SurgeryNagoya University Graduate School and School of MedicineNagoyaJapan
  2. 2.Department of Clinical Oncology and ChemotherapyNagoya University Graduate School and School of MedicineNagoyaJapan

Personalised recommendations